Evidence map›Paper›PMID 34100748›Full record

ArticleThe journal of international advanced otology2021

A Multicenter Retrospective Case Review of Outcomes and Complications of S53P4 Bioactive Glass.

Colin G Leonard, Sinead McNally, Mark Adams, Susie Hampton, Edward McNaboe, C Ekambar E Reddy, Neil A Bailie

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in The journal of international advanced otology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Colin G LeonardDepartment of Otolaryngology-Head and Neck Surgery, Royal Victoria Hospital, Belfast, Northern Ireland.
Sinead McNallyDepartment of Otolaryngology-Head and Neck Surgery, Craigavon Area Hospital, Craigavon, Northern Ireland.
Mark AdamsDepartment of Otolaryngology-Head and Neck Surgery, Royal Victoria Hospital, Belfast, Northern Ireland.
Susie HamptonDepartment of Otolaryngology-Head and Neck Surgery, Royal Victoria Hospital, Belfast, Northern Ireland.
Edward McNaboeDepartment of Otolaryngology-Head and Neck Surgery, Craigavon Area Hospital, Craigavon, Northern Ireland.
C Ekambar E ReddyDepartment of Otolaryngology-Head and Neck Surgery, Craigavon Area Hospital, Craigavon, Northern Ireland.
Neil A BailieDepartment of Otolaryngology-Head and Neck Surgery, Royal Victoria Hospital, Belfast, Northern Ireland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe objective of this multicenter retrospective case review was to assess the natural clinical course, efficacy, and safety of mastoid obliteration with S53P4 Bioactive Glass (bioactive glass).

methodsRetrospective case note review in a regional Tertiary Referral Centre and District General Hospital. Patients undergoing mastoid cavity obliteration as part of primary or secondary procedure with bioactive glass between 2012 and 2018. Outcome measures were assessed from a prospectively collated database and case note review. Primary outcomes were the common morbidities of a mastoid cavity; dry or discharging ear (Merchant's scale), vertigo in cold air, and a watertight middle ear. Patients were also assessed for audiological outcomes and recidivism.

resultsNinety patients were included. During the follow-up period, (mean, 22 months; range, 6-59 months) cholesteatoma recidivism was observed in 2% of ears (2 patients). An acceptably dry (Merchant Grade 0-1) ear was achieved in 91% of all ears (95% primary cases, 80% secondary cases). Delayed healing of the graft in the external ear canal retaining the S53P4BAG Bioactive Glass (BonAlive Ò (BonAlive Ò Biomaterials Ltd., Turku, Finland)) within the mastoid occurred in 13% (12 ears). However, in all cases, conservative management resulted in complete healing.

conclusionsBioactive glass provides a safe and effective means of mastoid obliteration. Complications including overlay graft failure and slow epithelialization, resulting in prolonged postoperative discharge (up to 2 months) and dehiscence into the external ear canal, do not preclude full recovery and may be successfully managed conservatively.

Indexed as

Cholesteatoma, Middle EarOtologic Surgical ProceduresFinlandHumansMastoidRetrospective StudiesTreatment Outcome

Identifiers

PMID34100748
PMCPMC9450276

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.